Question 1

What are the main strengths of investing in S2?

Accepted Answer

The main strengths of investing in Sanofi include: Dupixent Blockbuster Success: Sanofi's Dupixent achieved €13 billion sales in 2024 with patent protection beyond 2031, targeting €22 billion by 2030, providing exceptional revenue visibility and growth runway., Consistent Dividend Growth: The company offers 30 consecutive years of dividend increases with proposed €3.92 per share for 2024, demonstrating reliable shareholder returns and financial stability., Strong Pipeline and Innovation: With 86 clinical-stage projects and 31 in Phase 3, launches contributed 11% of sales with new blockbuster Beyfortus, showcasing successful R&D execution and portfolio diversification..

Question 2

What are the potential drawbacks of investing in S2?

Accepted Answer

Potential drawbacks of investing in Sanofi include: Pipeline Execution Risk: The recent itepekimab Phase 3 failure caused 6% stock decline, highlighting significant risks in replacing Dupixent revenues as competition approaches post-2031., Pricing Pressure and Competition: Dupixent faces U.S. pricing pressures and emerging IL-13/JAK inhibitor competition, while Aubagio (€2 billion sales) loses patent protection imminently., Post-Dupixent Transition Challenge: Despite pipeline progress, uncertainty remains about Sanofi's ability to replace Dupixent's massive earnings contribution once biosimilar competition emerges after 2031..

Question 3

What are the key financial metrics for S2?

Accepted Answer

Key financial metrics for Sanofi include: Market Cap: $16.08 billion, Current Price: $357.16, Dividend Yield: 0.93%.

Sanofi

Key Statistics

Valuation

Trading Info

52 Week

Dividends

Detailed View

S2

ESG Ratings